A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

QR Code

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

Chung-Shien Lee,1,2 Sandhya Sharma,3 Emily Miao,4 Cheryl Mensah,5 Kevin Sullivan,2 Nagashree Seetharamu2 1Department of Clinical Health Professions, St. John’s University, College of Pharmacy and Health Sciences, Queens, NY 11439, USA; 2Division of Medical Oncology and Hematology, Northwel...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2020
Sujets:	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/8b542e20ae0a4c32b9f76e780154d06b
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
par: Ling-Ling Kong, et autres
Publié: (2017)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
par: Paula Aldaz, et autres
Publié: (2021)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
par: Svetlana V. Odintsova, et autres
Publié: (2020)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
par: Sareshma Sudhesh Dev, et autres
Publié: (2021)

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
par: Xuan Zhou, et autres
Publié: (2021)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
par: Tian Tian, et autres
Publié: (2021)

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
par: Weiguo Gu, et autres
Publié: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
par: Wen M, et autres
Publié: (2018)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
par: Liesbeth M. Hondelink, MD, et autres
Publié: (2021)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
par: Brazel D, et autres
Publié: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
par: Gan J, et autres
Publié: (2021)

Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, inhibits colorectal cancer stem cell growth
par: YingYing He, et autres
Publié: (2021)

New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors
par: Ana Podolski-Renić, et autres
Publié: (2021)

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
par: Yukari Tsubata, et autres
Publié: (2021)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
par: Santarpia M, et autres
Publié: (2017)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
par: Yundeok Kim, et autres
Publié: (2021)

Targeted Therapies in Cancer: To Be or Not to Be, Selective
par: Skye Montoya, et autres
Publié: (2021)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
par: Alexey A. Bogdanov, et autres
Publié: (2021)

Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors
par: Hyeok-Jae Jang, et autres
Publié: (2021)

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer
par: Cristina Minnelli, et autres
Publié: (2021)

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
par: Masatomo Ueda, et autres
Publié: (2021)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
par: Sergey V. Goryaynov
Publié: (2021)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
par: Facchinetti F, et autres
Publié: (2019)

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
par: Petrushev B, et autres
Publié: (2016)

Immunohistochemical Evaluation and Clinicopathological Correlation of Mer and Axl Tyrosine Kinase TAM Receptors in Cutaneous Melanoma
par: Andrea Pontara, et autres
Publié: (2020)

The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
par: Kamil D. Kaplanov
Publié: (2021)

Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
par: Raj Kumar Mongre, et autres
Publié: (2021)

The Risk of QTc Prolongation in Non-Diabetic and Diabetic Patients Taking Tyrosine Kinase Inhibitors (TKIs)- A Patient Safety Project at a Private Oncology Practice
par: Zhongju Lu, et autres
Publié: (2021)

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
par: Agnieszka Kaczmarska, et autres
Publié: (2021)

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
par: Ling Peng, et autres
Publié: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
par: Nathaniel Wiest, et autres
Publié: (2021)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
par: Syahruddin E, et autres
Publié: (2018)

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors
par: Adina Gerson-Gurwitz, et autres
Publié: (2021)

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
par: Tran PN, et autres
Publié: (2016)

Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
par: Tan BK, et autres
Publié: (2021)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
par: Akiko Takahashi, et autres
Publié: (2018)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
par: Sánchez-Herrero Estela, et autres
Publié: (2020)

MET Receptor Tyrosine Kinase Regulates Lifespan Ultrasonic Vocalization and Vagal Motor Neuron Development
par: Anna K. Kamitakahara, et autres
Publié: (2021)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
par: Michela Verzè, et autres
Publié: (2021)

Oligoprogression in Non-Small Cell Lung Cancer
par: Daijiro Harada, et autres
Publié: (2021)